ライフサイエンスコーパス: granulocyte colony-stimulating factor

1 of NMO lesions in mice made neutrophilic by granulocyte colony stimulating factor.

2 duce proinflammatory genes, such as CCL2 and granulocyte colony-stimulating factor.

3 ing recombinant zebrafish erythropoietin and granulocyte colony-stimulating factor.

4 obilization induced by a CXCR4 antagonist or granulocyte colony-stimulating factor.

5 nia in G6PC3 deficiency and responds well to granulocyte colony-stimulating factor.

6 th increased levels of circulating IL-17 and granulocyte colony-stimulating factor.

7 ecreted protein Bv8, which is upregulated by granulocyte colony-stimulating factor.

8 (ethylene glycol) modified recombinant human granulocyte-colony stimulating factor.

9 nors, and is synergistic in combination with granulocyte-colony stimulating factor.

10 den but was augmented by coadministration of granulocyte-colony stimulating factor.

11 usion, tumor necrosis factor inhibitors, and granulocyte colony-stimulating factors.

12 of up to two 28-day cycles); or intravenous granulocyte colony-stimulating factor (300 mug/m(2) per

13 tarabine 2,000 mg/m(2)/dose on days 1-5; and granulocyte-colony stimulating factor 5 ug/kg/dose, days

14 3 ligand, interleukin-3, interleukin-6, and granulocyte colony-stimulating factor (5 GFs) either alo

15 Granulocyte colony-stimulating factor, a stem cell mobil

16 in systemic inflammatory markers, including granulocyte colony-stimulating factor (adjusted OR 2.8 [

17 nd quantitatively more HSPC from the BM than granulocyte colony-stimulating factor alone, including i

18 It involves subcutaneous injections of granulocyte-colony-stimulating factor/AMD3100 to mobiliz

19 bute to an infectious phenotype such as anti-granulocyte colony stimulating factor and anti-IFN-alpha

20 benefit could be gained by administration of granulocyte colony-stimulating factor and AMD3100.

21 the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via

22 n 1beta, monocyte chemotactic protein 1, and granulocyte colony-stimulating factor and decreased leve

23 ssor cells, which release elevated levels of granulocyte colony-stimulating factor and granulocyte ma

24 CCL1, CCL2, CCL3, CCL5), and growth factors (granulocyte colony-stimulating factor and granulocyte-ma

25 Within 4 days, bone marrow cells cultured in granulocyte colony-stimulating factor and granulocyte-ma

26 l severity (e.g. decreased responsiveness to granulocyte colony-stimulating factor and increased leuk

27 ficient) mice, they maintained expression of granulocyte colony-stimulating factor and leukemia inhib

28 Stat3 in response to moderate doses of both granulocyte-colony stimulating factor and IL-6.

29 tion prevented CXCL12 induction and improved granulocyte-colony stimulating factor and ischemia-induc

30 e primed macrophages in adulthood and raised granulocyte-colony stimulating factor and neutrophil cou

31 l expressed and presumably secreted), G-CSF (granulocyte-colony-stimulating factor) and MMP2 (matrix

32 d increased BAL fluid IL-1alpha, IL-6, IL-8, granulocyte colony-stimulating factor, and GM-CSF levels

33 luid myeloperoxidase, IL-8, IL-1alpha, IL-6, granulocyte colony-stimulating factor, and GM-CSF levels

34 1983) or ADE versus fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (F

35 , and etoposide; or fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin.

36 select interleukins, growth factors such as granulocyte colony-stimulating factor, and l-ferritin, h

37 reduced concentrations of interleukin-1beta, granulocyte colony-stimulating factor, and matrix metall

38 CCR2 and CX3CR1 up-regulation, whereas CCL1, granulocyte colony-stimulating factor, and MIP1alpha wer

39 ") CLAG-M (cladribine, high-dose cytarabine, granulocyte colony-stimulating factor, and mitoxantrone)

40 h significantly higher IL-1beta, IL-6, IL-8, granulocyte colony-stimulating factor, and monocyte chem

41 , soluble vascular cell adhesion molecule-1, granulocyte colony-stimulating factor, and soluble Fas.

42 ls produced higher levels of interleukin-10, granulocyte colony-stimulating factor, and transforming

43 icin 120 mg/m(2) and ifosfamide 9 g/m(2) and granulocyte colony-stimulating factor (arm A) or to rece

44 a levels of interleukin-1alpha and -beta and granulocyte-colony stimulating factor as well as increas

45 atory protein 1alpha, interleukin 1beta, and granulocyte colony-stimulating factor, as well as interl

46 on of the knob-domain of Ab-coil with bovine granulocyte colony-stimulating factor (bGCSF) results in

47 and many were prevented by interleukin-1 or granulocyte colony-stimulating factor blockade, revealin

48 Neutralizing granulocyte-colony stimulating factor blocked susceptibi

49 After a short course of granulocyte colony stimulating factor, bone marrow mesen

50 locyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, CCL2, and CCL5, w

51 O mice had decreased concentrations of IL-6, granulocyte colony stimulating factor, chemokine CXC lig

52 pheral blood CD34(+) cells were mobilized by granulocyte colony stimulating factor, collected via aph

53 fts were mobilized with cyclophosphamide and granulocyte colony-stimulating factor, collected by peri

54 tely linked to innate immune cell expansion (granulocyte colony-stimulating factor), cytotoxicity (in

55 a monocyte differentiation program in human granulocyte colony-stimulating factor-dependent neutroph

56 ta show that hematopoietic stress, including granulocyte colony-stimulating factor, do not increase t

57 mune illness, and stroke in donors receiving granulocyte colony-stimulating factor during this period

58 otein-1, monocyte chemotactic protein-3, and granulocyte-colony stimulating factor during the acute p

59 Post-transplantation, a combination of granulocyte colony-stimulating factor, erythropoietin, a

60 d fluorouracil 750 mg/m2 IV over 5 days with granulocyte colony-stimulating factor, every 3 weeks).

61 In NK cell-deficient mice, granulocyte colony-stimulating factor-expanded neutrophi

62 mly assigned to fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) or to FLAG

63 nsivist-led service, meropenem, and adjuvant granulocyte colony-stimulating factor for confirmed meli

64 l transplantation, with a five-day course of granulocyte colony stimulating factor (G-CSF) as the mos

65 Granulocyte colony stimulating factor (G-CSF) may enhanc

66 gation of BSA, beta2-microglobulin (beta2m), granulocyte colony stimulating factor (G-CSF), and three

67 d neutrophil-activating protein 78 (ENA-78), granulocyte colony stimulating factor (G-CSF), granulocy

68 Eighteen molecules (interleukine (IL)-1beta, granulocyte colony stimulating factor (G.CSF), IL-13, IL

69 Here, we demonstrate that granulocyte colony-stimulating factor (G-CSF) activates

70 with CSF3R truncation mutations; therapeutic granulocyte colony-stimulating factor (G-CSF) administra

71 to the treatment when forced into cycle via granulocyte colony-stimulating factor (G-CSF) administra

72 the stabilization of the therapeutic protein granulocyte colony-stimulating factor (G-CSF) against st

73 ersely, the myeloproliferation was driven by granulocyte colony-stimulating factor (G-CSF) and admini

74 Granulocyte colony-stimulating factor (G-CSF) and chemok

75 phil expansion and migration by antagonizing granulocyte colony-stimulating factor (G-CSF) and chemok

76 yte transfusions from donors stimulated with granulocyte colony-stimulating factor (G-CSF) and dexame

77 We assessed the safety and efficacy of granulocyte colony-stimulating factor (G-CSF) and haemop

78 sed body weight, and increased production of granulocyte colony-stimulating factor (G-CSF) and IL-1be

79 -response genes in mucosal RNA and increased granulocyte colony-stimulating factor (G-CSF) and IP-10

80 o myeloid lineage specification, we compared granulocyte colony-stimulating factor (G-CSF) and macrop

81 Rgamma) produced severely reduced amounts of granulocyte colony-stimulating factor (G-CSF) and of nit

82 AE, in response to systemic up-regulation of granulocyte colony-stimulating factor (G-CSF) and the EL

83 stigates the potential protective effects of granulocyte colony-stimulating factor (G-CSF) and underl

84 or neutrophil response despite high doses of granulocyte colony-stimulating factor (G-CSF) are at gre

85 independence 1 (Gfi1) and the growth factor granulocyte colony-stimulating factor (G-CSF) are indivi

86 CAIX is indispensable for the production of granulocyte colony-stimulating factor (G-CSF) by hypoxic

87 ith the clinically relevant mobilizing agent granulocyte colony-stimulating factor (G-CSF) caused rap

88 ), along with local interleukin (IL)-12, and granulocyte colony-stimulating factor (G-CSF) concentrat

89 , MIP-1beta, and IL-15 and semen eotaxin and granulocyte colony-stimulating factor (G-CSF) concentrat

90 ation of bone marrow-derived stem cells with granulocyte colony-stimulating factor (G-CSF) could prom

91 is was 0.4 x 10(9)/L, and median ANC without granulocyte colony-stimulating factor (G-CSF) during fol

92 Granulocyte colony-stimulating factor (G-CSF) effectivel

93 Finally, the concurrent administration of granulocyte colony-stimulating factor (G-CSF) enhanced R

94 The inherent disadvantages of using granulocyte colony-stimulating factor (G-CSF) for hemato

95 marrow into peripheral blood by the cytokine granulocyte colony-stimulating factor (G-CSF) has become

96 Granulocyte colony-stimulating factor (G-CSF) has been s

97 Although granulocyte colony-stimulating factor (G-CSF) has been s

98 In G6PC3-deficient patients, granulocyte colony-stimulating factor (G-CSF) improves n

99 d the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G-CSF) in mobiliz

100 We assessed the efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in steroid

101 ne recommended primary prophylaxis (PP) with granulocyte colony-stimulating factor (G-CSF) instead of

102 Granulocyte colony-stimulating factor (G-CSF) is a regul

103 Human granulocyte colony-stimulating factor (G-CSF) is an endo

104 stem/progenitor cell (HSPC) mobilization by granulocyte colony-stimulating factor (G-CSF) is mediate

105 Granulocyte colony-stimulating factor (G-CSF) is used cl

106 Granulocyte colony-stimulating factor (G-CSF) is widely

107 ocyte chemoattractive protein 1 (MCP-1), and granulocyte colony-stimulating factor (G-CSF) levels in

108 In contrast, granulocyte colony-stimulating factor (G-CSF) levels wer

109 Granulocyte colony-stimulating factor (G-CSF) mediates "

110 Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize p

111 antithymocyte globulin (ATG) plus pegylated granulocyte colony-stimulating factor (G-CSF) preserves

112 Investigations in this model revealed that granulocyte colony-stimulating factor (G-CSF) produced b

113 was to describe the effect of antibiotic and granulocyte colony-stimulating factor (G-CSF) prophylaxi

114 Guidelines advise primary granulocyte colony-stimulating factor (G-CSF) prophylaxi

115 who were administered T-BEP received primary granulocyte colony-stimulating factor (G-CSF) prophylaxi

116 Purpose To describe outcomes after granulocyte colony-stimulating factor (G-CSF) prophylaxi

117 opoietic counterpart, 2 designs bound to the granulocyte colony-stimulating factor (G-CSF) receptor a

118 ed downregulation of the Csf3r gene, reduced granulocyte colony-stimulating factor (G-CSF) receptor l

119 1 (LEF-1), which plays a definitive role in granulocyte colony-stimulating factor (G-CSF) receptor-t

120 of-function mutations in CSF3R, encoding the granulocyte colony-stimulating factor (G-CSF) receptor.

121 elopoiesis prevented HSPC mobilization after granulocyte colony-stimulating factor (G-CSF) stimulatio

122 es the risk of myelotoxicity and may require granulocyte colony-stimulating factor (G-CSF) support.

123 greatest differential was with the cytokine granulocyte colony-stimulating factor (G-CSF) that cause

124 BM) to the blood circulation by the cytokine granulocyte colony-stimulating factor (G-CSF) through co

125 rleukin-17 (IL-17) induced the expression of granulocyte colony-stimulating factor (G-CSF) through nu

126 lls for transplantation, use of the cytokine granulocyte colony-stimulating factor (G-CSF) to mobiliz

127 mononuclear cells (BMMC) and the ability of granulocyte colony-stimulating factor (G-CSF) to mobiliz

128 vances in the therapeutic use of recombinant granulocyte colony-stimulating factor (G-CSF) to promote

129 ulate MTA1 expression in neuronal cells, and granulocyte colony-stimulating factor (G-CSF) was chosen

130 erleukin 1 receptor antagonist (IL-1Ra), and granulocyte colony-stimulating factor (G-CSF) were raise

131 ls were randomized to receive plerixafor and granulocyte colony-stimulating factor (G-CSF), agents kn

132 er levels of cytokines/chemokines, including granulocyte colony-stimulating factor (G-CSF), and enhan

133 ony formation, decreased in vivo response to granulocyte colony-stimulating factor (G-CSF), and impai

134 a), tumor necrosis factor alpha (TNF-alpha), granulocyte colony-stimulating factor (G-CSF), and inter

135 Furthermore, the combination of granulocyte colony-stimulating factor (G-CSF), BIO5192,

136 Neutrophil mobilization responses to granulocyte colony-stimulating factor (G-CSF), CXCL2, or

137 lassemic patients mobilized with hydroxyurea+granulocyte colony-stimulating factor (G-CSF), G-CSF, Pl

138 interleukin 1beta (IL-1beta), IL-6, IL-17A, granulocyte colony-stimulating factor (G-CSF), granulocy

139 Interleukin (IL)-6, IL-8, granulocyte colony-stimulating factor (G-CSF), interfero

140 15, tumor necrosis factor alpha (TNF-alpha), granulocyte colony-stimulating factor (G-CSF), interfero

141 LCs expressed significantly higher levels of granulocyte colony-stimulating factor (G-CSF), interleuk

142 MIP-1beta, granulocyte colony-stimulating factor (G-CSF), interleuk

143 IL-15), IL-18, gamma interferon (IFN-gamma), granulocyte colony-stimulating factor (G-CSF), monocyte

144 Tlr4 and Myd88 and are the primary source of granulocyte colony-stimulating factor (G-CSF), the key g

145 Granulocyte colony-stimulating factor (G-CSF), the proto

146 After administration of granulocyte colony-stimulating factor (G-CSF), there is

147 ophil count and their priming is mediated by granulocyte colony-stimulating factor (G-CSF), which acc

148 ts with WHIM syndrome are often treated with granulocyte colony-stimulating factor (G-CSF), which can

149 cally, TLR4 and NOD1 synergistically induced granulocyte colony-stimulating factor (G-CSF), which was

150 4+ peripheral-blood stem cells, mobilized by granulocyte colony-stimulating factor (G-CSF), which wer

151 Recently, it has also been shown that granulocyte colony-stimulating factor (G-CSF)-induced BV

152 Nociceptor neurons drive granulocyte colony-stimulating factor (G-CSF)-induced HS

153 Functional studies demonstrated elevated granulocyte colony-stimulating factor (G-CSF)-induced pr

154 ately 35% at 1 year after transplantation of granulocyte colony-stimulating factor (G-CSF)-mobilized

155 nse to damaged cells, promoting an excessive granulocyte colony-stimulating factor (G-CSF)-regulated

156 capitulates a Gfi1 loss-of-function block to granulocyte colony-stimulating factor (G-CSF)-stimulated

157 opulation that appears in the circulation of granulocyte colony-stimulating factor (G-CSF)-treated do

158 stem cell (HSC) mobilization in response to granulocyte colony-stimulating factor (G-CSF).

159 ing cells in the intestine and production of granulocyte colony-stimulating factor (G-CSF).

160 ion of CSF3R, which encodes the receptor for granulocyte colony-stimulating factor (G-CSF).

161 magnitude to a standard multi-day regimen of granulocyte colony-stimulating factor (G-CSF).

162 MIP-2)/CXCL2, IP-10/CXCL10, MIP-1alpha/CCL3, granulocyte colony-stimulating factor (G-CSF)/CSF3, CXCL

163 increases in IL-1alpha/beta, IL-6/IL-12(p40)/granulocyte colony-stimulating factor (G-CSF)/keratinocy

164 ve mice but can be induced by treatment with granulocyte colony-stimulating factor (G-CSF/Csf3) or by

165 Patients received granulocyte colony-stimulating factor (G-CSF; 10 microg/

166 he combination of stem cell factor (SCF) and granulocyte-colony stimulating factor (G-CSF) (SCF+G-CSF

167 ies have found that the neuroactive cytokine granulocyte-colony stimulating factor (G-CSF) alters coc

168 he neuroprotective effects of the cytokines, granulocyte-colony stimulating factor (G-CSF) and stem c

169 Previous work from our group has identified granulocyte-colony stimulating factor (G-CSF) as a neuro

170 Treatment with granulocyte-colony stimulating factor (G-CSF) causes HSC

171 The IL-23/IL-17/granulocyte-colony stimulating factor (G-CSF) cytokine-c

172 by a novel mechanism in which tumor-derived granulocyte-colony stimulating factor (G-CSF) directs ex

173 few published cases, there is evidence that granulocyte-colony stimulating factor (G-CSF) in patient

174 The cytokine granulocyte-colony stimulating factor (G-CSF) is commonl

175 ence coverage was obtained by reducing human granulocyte-colony stimulating factor (G-CSF) prior to M

176 Granulocyte-colony stimulating factor (G-CSF) promotes m

177 Using a granulocyte-colony stimulating factor (G-CSF) receptor k

178 Following VSG, circulating granulocyte-colony stimulating factor (G-CSF) was increa

179 of four drugs: antithymocyte globulin (ATG), granulocyte-colony stimulating factor (G-CSF), a dipepti

180 her key inflammatory factors including IL-8, granulocyte-colony stimulating factor (G-CSF), IL-33, IL

181 he metastatic tumors we examined overexpress granulocyte-colony stimulating factor (G-CSF), which exp

182 kaemia (AML) samples, and downregulated upon granulocyte-colony stimulating factor (G-CSF)- mediated

183 ncouraging outcomes after transplantation of granulocyte-colony stimulating factor (G-CSF)- primed un

184 transfer of transplant (tx), tumor (tm), and granulocyte-colony stimulating factor (g-csf)-expanded M

185 marrow adipose tissue, in part via increased granulocyte-colony stimulating factor (G-CSF).

186 released into the circulation in response to granulocyte-colony stimulating factor (G-CSF).

187 aly in adulthood due to the up-regulation of granulocyte-colony stimulating factor (G-CSF); these eff

188 is, we identify the proinflammatory cytokine granulocyte-colony-stimulating factor (G-CSF or Csf-3) a

189 -term repopulating capacity as well as hyper granulocyte-colony-stimulating factor (G-CSF)-induced mo

190 ]) and differences (interleukin-6 [IL-6] and granulocyte colony-stimulating factor [G-CSF]) elicited

191 okines (interferon gamma, interleukin 6, and granulocyte colony-stimulating factor [G-CSF]) were high

192 lammatory mediators (including CXCL1, CXCL2, granulocyte colony-stimulating factor [G-CSF], interleuk

193 models: (i) three different ligands based on granulocyte colony-stimulating factor GCSF homo-dimeric

194 al use of zebrafish Tpo, erythropoietin, and granulocyte colony stimulating factor (Gcsf) allowed the

195 ignificant controversy surrounds the role of granulocyte colony stimulating factor (GCSF) in levamiso

196 stered with Flt3 ligand (FL) (days 1-10) and granulocyte colony-stimulating factor (GCSF) (days 4-10)

197 Granulocyte colony-stimulating factor (Gcsf) drives the

198 Human granulocyte colony-stimulating factor (GCSF) is a well-k

199 GSD-Ib patients with incomplete response to granulocyte colony-stimulating factor (GCSF) treatment d

200 89) were randomized to 1) ATG and pegylated granulocyte colony-stimulating factor (GCSF), 2) ATG alo

201 nterleukin (IL)-4, IL-6, IL-8, IL-10, IL-15, granulocyte colony-stimulating factor (GCSF), MCP-1, tum

202 lin (ATG), as well as the mobilization agent granulocyte colony-stimulating factor (GCSF), to reverse

203 (6S,7S,8S)-1a and (6R,7S,8S)-1b inhibited granulocyte colony-stimulating factor (GCSF)-stimulated

204 We also show that granulocyte colony-stimulating factors (GCSF and GM-CSF)

205 Granulocyte colony-stimulating factors (GCSF) have been

206 nterleukin-2, IFN alfa-2b (IFN-alpha-2b) and granulocyte colony-stimulating factor given every 21 day

207 erleukin-17, basic fibroblast growth factor, granulocyte colony-stimulating factor, granulocyte macro

208 ulating levels of IL-1beta, IL-1alpha, IL-6, granulocyte-colony stimulating factor, granulocyte-macro

209 emonstrate that a post-BMT regimen of either granulocyte-colony stimulating factor, growth hormone, p

210 Since granulocyte colony-stimulating factor has been recently

211 Human erythropoietin (hEPO) or granulocyte colony-stimulating factor (hGCSF) was indepe

212 and exhibited significantly lower levels of granulocyte colony stimulating factor, IL-8, macrophage

213 of machrophage colony stimulating factor and granulocyte colony stimulating factor in splenic macroph

214 of meropenem, and adjunctive treatment with granulocyte colony-stimulating factor in 1998.

215 gG deposits and the pathophysiologic role of granulocyte colony-stimulating factor in exacerbation of

216 CCL2/monocyte chemoattractant protein 1, and granulocyte colony-stimulating factor in lung homogenate

217 2 and 8 of a 21-day cycle with prophylactic granulocyte colony-stimulating factor in the heavily pre

218 ed in diabetic mice lacking the receptor for granulocyte colony-stimulating factor in their marrow-de

219 f serum cytokines showed increased levels of granulocyte colony-stimulating factor in transgenic anim

220 r stem cell mobilization in combination with granulocyte-colony stimulating factor in patients with n

221 dvent of hematopoietic cytokines (especially granulocyte colony-stimulating factor) in shortening the

222 Recombinant mouse granulocyte colony-stimulating factor increased survival

223 Treatment with a high dose of granulocyte colony-stimulating factor increases neutroph

224 In addition, granulocyte colony-stimulating factor -induced mobilizat

225 mobilized more circulating neutrophils after granulocyte colony-stimulating factor infusion compared

226 sis demonstrated significant upregulation of granulocyte colony-stimulating factor, interferon gamma,

227 d plasma levels of cytokines (interleukin 6, granulocyte colony-stimulating factor, interleukin 1 rec

228 e elevated in the posttransplantation phase: granulocyte colony-stimulating factor, interleukin-8, ti

229 eraction chromatography of recombinant human granulocyte colony stimulating factor is demonstrated.

230 Granulocyte-colony stimulating factor is the treatment o

231 A-EX) mice had less IL-6, interleukin 12p40, granulocyte colony-stimulating factor, keratinococyte-de

232 te proinflammatory cytokines (interleukin-6, granulocyte colony-stimulating factor, keratinocyte chem

233 rotein-1, macrophage inflammatory protein-2, granulocyte colony-stimulating factor, keratinocyte chem

234 rrelated with the production of 5 cytokines (granulocyte colony-stimulating factor, keratinocyte-deri

235 for 5 days on days 10-14; two cycles), with granulocyte-colony stimulating factor (lenograstim) supp

236 he treatment diminished circulating IL-6 and granulocyte colony-stimulating factor levels and limited

237 locyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, macrophage colony

238 ith no prophylactic use of recombinant human granulocyte-colony stimulating factor mandated in this g

239 are (either fludarabine plus cytarabine plus granulocyte colony-stimulating factor, mitoxantrone plus

240 nsplantation (HCT), either marrow (n = 4) or granulocyte-colony stimulating factor mobilized peripher

241 D161(hi) cells from umbilical cord blood and granulocyte colony stimulating factor-mobilized leukaphe

242 e globulin (ATG) followed by the infusion of granulocyte colony-stimulating factor-mobilized grafts.

243 nditioned with 2-Gy TBI and given autologous granulocyte colony-stimulating factor-mobilized leukocyt

244 Following the infusion of PMF and normal granulocyte colony-stimulating factor-mobilized peripher

245 increasing use of mismatched, unrelated, and granulocyte colony-stimulating factor-mobilized peripher

246 tation of primary functional human MEPs from granulocyte colony-stimulating factor-mobilized peripher

247 ct of a set of immune cells contained within granulocyte colony-stimulating factor-mobilized peripher

248 er serum levels of interleukin (IL)-6, IL-8, granulocyte colony-stimulating factor, monocyte chemoatt

249 ecreased interferon-inducible protein 10 and granulocyte colony-stimulating factor more than did nore

250 Reduction of neutrophil functions via granulocyte colony-stimulating factor neutralization sig

251 ary vaccine recipients had maximal levels of granulocyte-colony-stimulating factor on days 6-7 after

252 iesis-stimulating agents in combination with granulocyte colony-stimulating factor or all-trans-retin

253 Supplementation of imatinib with granulocyte colony-stimulating factor or arsenic trioxid

254 d after stimulation with increasing doses of granulocyte-colony stimulating factor or IL-6.

255 sly every 3 weeks, plus prednisone daily and granulocyte colony-stimulating factor) or the other andr

256 was also associated with elevated levels of granulocyte colony-stimulating factor (P = .02).

257 0.002), IL-6 (P = 0.002), IL-8 (P = 0.026), granulocyte colony-stimulating factor (P = 0.002), and m

258 PEGylated recombinant human granulocyte colony stimulating factor (pegfilgrastim) is

259 ene glycol) (PEG), such as recombinant human granulocyte-colony stimulating factor (PEGylated rhG-CSF

260 lone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improv

261 fety of erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive ca

262 ministration of clofarabine, cytarabine, and granulocyte-colony stimulating factor priming.

263 Filgrastim, an analog for granulocyte colony-stimulating factor produced by recomb

264 tors for erythropoietin, thrombopoietin, and granulocyte colony-stimulating factor, provided an expla

265 -derived CD34(+) cells mobilized in blood by granulocyte colony-stimulating factor, purified WAT-CD34

266 demonstrate that activating mutations in the granulocyte colony stimulating factor receptor (CSF3R),

267 Antibodies that are agonists for the granulocyte colony stimulating factor receptor were sele

268 hosphatase-1 (SHP-1)-dependent inhibition of granulocyte colony-stimulating factor receptor (G-CSFR)

269 companied by mutations in CSF3R encoding the granulocyte colony-stimulating factor receptor (G-CSFR)

270 Mutations in the CSF3 granulocyte colony-stimulating factor receptor CSF3R hav

271 s and monocytes is primarily governed by the granulocyte colony-stimulating factor receptor family (C

272 me high frequency recurrent mutations in the granulocyte colony-stimulating factor receptor gene CSF3

273 cytokine receptors (erythropoietin receptor, granulocyte colony-stimulating factor receptor, and MPL)

274 of type I and II cytokine receptors, except granulocyte colony-stimulating factor receptor, which su

275 in the secretory pathway and is required for granulocyte colony-stimulating factor receptor-mediated

276 ed high-frequency oncogenic mutations in the granulocyte-colony stimulating factor receptor (CSF3R) i

277 ause the erythropoietin, thrombopoietin, and granulocyte colony-stimulating factor receptors are all

278 ting factor alone, including in a setting of granulocyte colony-stimulating factor resistance.

279 Restoring Cebpa expression by granulocyte colony-stimulating factor reverses the db ph

280 s Stat3-NF-kappaB cross-talk, the release of granulocyte colony-stimulating factor, soluble intercell

281 ments with primary keratinocytes showed that granulocyte colony-stimulating factor stimulated Ras act

282 3-deficient cells showed hypersensitivity to granulocyte-colony stimulating factor, suggesting enhanc

283 aily oral cyclophosphamide administered with granulocyte colony-stimulating factor support for 15 wee

284 Primary granulocyte colony-stimulating factor support was requir

285 Unlike the natural granulocyte-colony stimulating factor that activates cel

286 Except for granulocyte colony-stimulating factor, these differences

287 In both patients, granulocyte colony-stimulating factor treatment normaliz

288 n antibacterial cytokine response comprising granulocyte colony-stimulating factor, tumor necrosis fa

289 d trial, eligible patients were treated with granulocyte colony-stimulating factor, underwent an aphe

290 osis, neutrophil count, type of peg-IFN, and granulocyte colony-stimulating factor use, none of these

291 terferon-gamma, tumor necrosis factor-alpha, granulocyte colony-stimulating factor, vascular-endothel

292 y every 3 weeks, 10 mg daily prednisone, and granulocyte colony-stimulating factor) versus abirateron

293 Granulocyte colony-stimulating factor was given between

294 Granulocyte colony-stimulating factor was prohibited.

295 d to support erythroid colony formation, and granulocyte colony-stimulating factor was required to su

296 The protein therapeutic granulocyte-colony stimulating factor was analyzed using

297 All patients tolerated granulocyte colony-stimulating factor well with minimal

298 protein levels of tumor necrosis factor and granulocyte colony-stimulating factor were rapidly upreg

299 serum levels of IFN-gamma, IL-12, IL-6, and granulocyte colony-stimulating factor were significantly

300 , and inflammatory cytokines (interleukin-8, granulocyte colony-stimulating factor) were elevated in